A Study to Collect and Evaluate the Safety and Efficacy Information of Korean Multiple Myeloma Patients Treated With REVLIMID®, After Approval of Marketing Authorization for New Drug in Korea
Clinical trial NCT02556905 · COMPLETED
Trial details
- NCT number
- NCT02556905
- Sponsor
- Celgene
- Status
- COMPLETED
- Study type
- OBSERVATIONAL
- Start date
- 2011-03-09
- Primary completion
- 2016-11-30
- Enrollment
- 624
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.